GlassScriptPhysician profile
William M Mclean
NPI 1558368357
$5,865.65
in general payments reported to CMS, 2019-2025
42 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,215 · 2022: $1,269 · 2023: $1,329 · 2024: $924 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $885.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $779.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.75 | 2021-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $333.30 | 2021-2025 | |
| Amgen INC. | $331.34 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $306.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $296.27 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $271.14 | 2021-2024 | |
| Astellas Pharma US INC | $161.67 | 2021-2023 | Myrbetriq |
| Opko Pharmaceuticals, LLC | $146.11 | 2023-2025 | Rayaldee |
| Merck Sharp & Dohme LLC | $141.99 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Vertex Pharmaceuticals Incorporated | $124.99 | 2025 | |
| Exact Sciences Corporation | $117.90 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.76 | 2021-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $105.00 | 2021-2024 | Livalo, Seglentis, Zoryve |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.